Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

Open access
Snijder, Berend, Vladimer, Gregory I, Krall, Nikolaus, Miura, Katsuhiro, Schmolke, Ann-Sofie, Kornauth, Christoph, Lopez de la Fuente, Oscar, Choi, Hye-Soo, van der Kouwe, Emiel, Gültekin, Sinan, Kazianka, Lukas, Bigenzahn, Johannes W, Hoermann, Gregor, Prutsch, Nicole, Merkel, Olaf, Ringler, Anna, Sabler, Monika, Jeryczynski, Georg, Mayerhoefer, Marius E, Simonitsch-Klupp, Ingrid, Ocko, Katharina, Felberbauer, Franz, Müllauer, Leonhard, Prager, Gerald W, Korkmaz, Belgin, Kenner, Lukas, Sperr, Wolfgang R, Kralovics, Robert, Gisslinger, Heinz, Valent, Peter, Kubicek, Stefan, Jäger, Ulrich, Staber, Philipp B, Superti-Furga, Giulio · 2017 · The Lancet Haematology

Abstract

BACKGROUND: Patients with refractory or relapsed haematological malignancies have few treatment options and short survival times. Identification of effective therapies with genomic-based precision medicine is hampered by intratumour heterogeneity and incomplete understanding of the contribution of various mutations within specific cancer phenotypes. Ex-vivo drug-response profiling in patient biopsies might aid effective treatment identification; however, proof of its clinical utility is limited. METHODS: We investigated the feasibility and clinical impact of multiparametric, single-cell, drug-response profiling in patient biopsies by immunofluorescence, automated microscopy, and image analysis, an approach we call pharmacoscopy. First, the ability of pharmacoscopy to separate responders from non-responders was evaluated retrospectively for a cohort of 20 newly diagnosed and previously untreated patients with acute myeloid leukaemia. Next, 48 patients with aggressive haematological malignancies were prospectively evaluated for pharmacoscopy-guided treatment, of whom 17 could receive the treatment. The primary endpoint was progression-free survival in pharmacoscopy-treated patients, as compared with their own progression-free survival for the most recent regimen on which they had progressive disease. This trial is ongoing and registered with ClinicalTrials.gov, number NCT03096821. FINDINGS: Pharmacoscopy retrospectively predicted the clinical response of 20 acute myeloid leukaemia patients to initial therapy with 88·1% accuracy. In this interim analysis, 15 (88%) of 17 patients receiving pharmacoscopy-guided treatment had an overall response compared with four (24%) of 17 patients with their most recent regimen (odds ratio 24·38 [95% CI 3·99-125·4], p=0·0013). 12 (71%) of 17 patients had a progression-free survival ratio of 1·3 or higher, and median progression-free survival increased by four times, from 5·7 (95% CI 4·1-12·1) weeks to 22·6 (7·4-34·0) weeks (hazard ratio 3·14 [95% CI 1·37-7·22], p=0·0075). INTERPRETATION: Routine clinical integration of pharmacoscopy for treatment selection is technically feasible, and led to improved treatment of patients with aggressive refractory haematological malignancies in an initial patient cohort, warranting further investigation. FUNDING: Austrian Academy of Sciences; European Research Council; Austrian Science Fund; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development; Anniversary Fund of the Austrian National Bank; MPN Research Foundation; European Molecular Biology Organization; and Swiss National Science Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(17)30208-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 177

Metadata

Authors
Snijder, B., Vladimer, G. I., Krall, N., Miura, K., Schmolke, A.-S., Kornauth, C., Lopez de la Fuente, O., Choi, H.-S., van der Kouwe, E., Gültekin, S., Kazianka, L., Bigenzahn, J. W., Hoermann, G., Prutsch, N., Merkel, O., Ringler, A., Sabler, M., Jeryczynski, G., Mayerhoefer, M. E., Simonitsch-Klupp, I., Ocko, K., Felberbauer, F., Müllauer, L., Prager, G. W., Korkmaz, B., Kenner, L., Sperr, W. R., Kralovics, R., Gisslinger, H., Valent, P., Kubicek, S., Jäger, U., Staber, P. B., & Superti-Furga, G.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2017-12
Volume
4
Issue
12
Pages
e595-e606
ISSN
2352-3026 (ISSN-L)
OpenAlex
W2769605488
Cited by
177
References
6
FWCI
8.50
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. https://app.cochat.ai/papers/10.1016/s2352-3026(17)30208-9
The paper
Snijder, B., Vladimer, G. I., Krall, N., Miura, K., Schmolke, A.-S., Kornauth, C., Lopez de la Fuente, O., Choi, H.-S., van der Kouwe, E., Gültekin, S., Kazianka, L., Bigenzahn, J. W., Hoermann, G., Prutsch, N., Merkel, O., Ringler, A., Sabler, M., Jeryczynski, G., Mayerhoefer, M. E., . . . Superti-Furga, G. (2017). Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(17)30208-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.